Phase I study of chromomycin A (NSC-58514).
D000230:Adenocarcinoma / Q000188:drug therapy; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001943:Breast Neoplasms / Q000188:drug therapy; D002118:Calcium / Q000097:blood; D002291:Carcinoma, Papillary / Q000188:drug therapy; D002865:Chromomycins / Q000627:therapeutic use / Q000633:toxicity*; D004938:Esophageal Neoplasms / Q000188:drug therapy; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D007889:Leiomyoma / Q000188:drug therapy; D007970:Leukopenia / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D009336:Necrosis / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D014062:Tongue Neoplasms / Q000188:drug therapy
D002865:Chromomycins; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase; D002118:Calcium